Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now later-stage tilt small index

Chronic Lung Disease: later-stage trial registry

6 of 10 indexed Chronic Lung Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Chronic Lung Disease: 10 US clinical trials tracked, 6 recruiting.

Chronic Lung Disease is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Tennessee, running 2 of these trials.

Enrollment posture brief

Registry condition chronic-lung-disease

OPEN 6 | RECR 60% | LATE 1 | EARLY 0 | RANK #1724 | SPON 2

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Chronic Lung Disease (this)60%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Chronic Lung Disease

Chronic Lung Disease lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Lung Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Lung Disease is recruiting above its size-band peers.

    6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chronic Lung Disease research.

    University of Tennessee accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Chronic Lung Disease enrolment sits around 375 participants.

    Median target enrolment is 375 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Chronic Lung Disease splits between interventional and observational designs.

    5 interventional and 5 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Open and recent trials

10 total, page 1 of 1

RECRUITING 1,100 participants

Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants

Medical College of Wisconsin

NCT00710112

RECRUITING NA 388 participants

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

University of Tennessee

NCT06374277

RECRUITING 375 participants

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

University of Michigan Rogel Cancer Center

NCT05866302

RECRUITING 100 participants

Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension

Temple University

NCT07151768

RECRUITING 90 participants

Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

Masonic Cancer Center, University of Minnesota

NCT05025774

RECRUITING NA 30 participants

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

MGH Institute of Health Professions

NCT06304207

ACTIVE NOT RECRUITING 600 participants

Utility of Lung Clearance Index Score As a Noninvasive Marker of Small Airways Disease

National Jewish Health

NCT03241420

ACTIVE NOT RECRUITING NA 90 participants

Inspiratory Muscle Training Immediately After Lung Transplantation

Ohio State University

NCT05309551

COMPLETED Phase 4 417 participants

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

MedImmune

NCT00233064

COMPLETED NA 26 participants

A Pilot Study of Pulmonary Function in Dysphagic Infants

University of Tennessee

NCT00831038

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Chronic Lung Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Liquid Palivizumab Biological
1 trials
Lyophilized Palivizumab Biological
1 trials
Infant Pulmonary Function Tests Procedure
1 trials
IMT- Placebo group Device
1 trials
IMT- Intervention group Device
1 trials
lung clearance index (LCI) Device
1 trials
Physical activity Other
1 trials
gene variations Genetic
1 trials

US sites by state

Facility locations filed on Chronic Lung Disease trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Tennessee 2 trials
Michigan 2 trials
Georgia 2 trials
California 2 trials
Wisconsin 1 trials
Washington 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Lung Disease page

10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Lung Disease condition card totals 10 registered trials; most-linked intervention Liquid Palivizumab; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.